Shopping Cart
- Remove All
- Your shopping cart is currently empty
BPI-9016M is an effective, orally active, and selective dual inhibitor of c-Met and AXL tyrosine kinases. It suppresses tumor cell growth, invasion, and migration of lung adenocarcinoma.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,680 | 8-10 weeks | |
50 mg | $2,190 | 8-10 weeks | |
100 mg | $3,100 | 8-10 weeks |
Description | BPI-9016M is an effective, orally active, and selective dual inhibitor of c-Met and AXL tyrosine kinases. It suppresses tumor cell growth, invasion, and migration of lung adenocarcinoma. |
In vitro | The IC50 of BPI-9016M in several lung adenocarcinoma cell lines ( A549, H1299, H1650, H1975, HCC827, and PC-9 cells) as well as in primary lung adenocarcinoma cells are ranged from 5.3 μM to 27.1 μM. BPI-9016M (3.1-50 μM) reduces the expression of c-Met, p-c-Met, p-AKT, and p-ERK in the H1299 and A549 cells in a dose-dependent manner. BPI-9016M (6.3-25 μM; 2 weeks) inhibited cell proliferation. BPI-9016M (12.5-50 μM; 24 hours) induces the accumulation of more tumor cells in the G1 phase [2]. |
In vivo | In PDX xenografts in NOD/SCID mice, BPI-9016M (60 mg/kg; p.o.; daily for 16 or 12 days) dramatically restrains tumor growth [2]. |
Molecular Weight | 460.43 |
Formula | C25H18F2N4O3 |
Cas No. | 1528546-94-2 |
Relative Density. | 1.431 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.